Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients? | Zendy

Monica Balzarotti | Zendy; Armando Santoro | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients?

Author(s) -

Monica Balzarotti,

Armando Santoro

Publication year - 2020

Publication title -

annals of translational medicine

Language(s) - English

Resource type - Journals

eISSN - 2305-5847

pISSN - 2305-5839

DOI - 10.21037/atm.2020.04.06

Subject(s) - medicine , pneumonitis , pembrolizumab , neutropenia , refractory (planetary science) , gastroenterology , lymphoma , adverse effect , oncology , toxicity , immunotherapy , cancer , lung , physics , astrobiology

Humanitas Cancer Center, Rozzano, Italy Correspondence to: Monica Balzarotti, MD. Via Alessandro Manzoni, 56, 20089 Rozzano, MI, Italy. Email: monica.balzarotti@cancercenter.humanitas.it. Provenance: This is an invited article commissioned by the Editorial Office, Annals of Translational Medicine. Comment on: Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol 2019;37:3291-9.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research